Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Blinatumomab and oral TKIs for the treatment of Ph ALL

Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA

Blinatumomab and oral TKIs for the treatment of Ph ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL

Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )

Real world management of multiple myeloma patients

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5...

Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results ( Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany )

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM...

Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients ( Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain )

FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

FORTE trial: Impact of minimal residual disease on multiple myeloma patients ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

Evaluation of MRD negativity in patients with relapsed or refractory multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

$Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )$

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma

Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma ( Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA )

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma

Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma ( Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA )

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in...

Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML ( Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA )

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Ponatinib, venetoclax and dexamethasone for patients with relapsed or...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

$Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )$

More from ecancer